Pasithea Therapeutics (NASDAQ:KTTA) Stock Pulls Back On Prfoit Booking

February 4, 2022

There was a sharp correction in the Pasithea Therapeutics (NASDAQ:KTTA) stock on Thursday as investors indulged in a bit of a selloff and it went down by as much as 6% as a consequence. That being said, it is also necessary to note that the biotech stock is still up by as much as 15% over the course of the past week. Trading Data On Thursday, KTTA stock ended lower…